+91 8617752708

International Journal of Biochemistry Research & Review, ISSN: 2231-086X,Vol.: 10, Issue.: 1


Optimizing the Aggregation Propensity of Therapeutic Monoclonal Antibodies against Cancer and Autoimmune Diseases: A Computational Study


Anna-Isavella G. Rerra1†, Vasiliki P. Grimanelli1†, Nikos C. Papandreou1 and Stavros J. Hamodrakas1*
1Department of Cell Biology and Biophysics, Faculty of Biology, University of Athens, Panepistimiopolis, Athens 157 01, Greece.

Article Information
(1) Rosario Gomez Garcia, Department of Biochemistry, Loyola University, USA.
(1) Wei-Gang Hu, Defence Research and Development Canada, Canada.
(2) Wagner Loyola, Brazilian Agricultural Research Corporation, Brazil.
(3) Mona Samir Hashem Mahmoud, National Research Centre, Egypt.
(4) Chia-Li Yu, National Taiwan University Hospital, Taipei, Taiwan.
(5) Benjamin Pineda, National Institute of Neurology and Neurosurgery, Mexico.
Complete Peer review History: http://sciencedomain.org/review-history/12974


Monoclonal antibodies (mAbs) represent the most promising and rapidly growing class of therapeutic compounds for treating a wide variety of human chronic and acute diseases.  Despite their benefits, a major drawback in the exploitation of antibodies is their tendency to form aggregates.  As a result, severe immunological reactions in patients have been recorded.

In this study, we investigated the susceptibility of a set of therapeutic monoclonal antibodies to form aggregates. We selected antibodies that have all been approved by the U. S. Food and Drug Administration and are indicated for the treatment of various types of cancer and autoimmune diseases. The AMYLPRED 2 consensus method was used to predict ‘aggregation-prone’ regions on the surface of these proteins.

These regions are conserved and observed in almost all monoclonal antibodies commercially available. Considering the amino acid sequences of these antibodies, common groups of ‘aggregation-prone’ regions were identified, called clusters. We successfully reduced or even fully eliminated ‘aggregation-prone’ groups (clusters) by specific ‘mutations’ of the amino acids with exposed side chains. This information may be useful in future studies of monoclonal antibodies by improving existing therapeutic products or by designing novel ones.

Keywords :

Aggregation-prone regions; monoclonal antibodies; aggregation propensity; cancer; autoimmune diseases.

Full Article - PDF    Page 1-15

DOI : 10.9734/IJBCRR/2016/23216

Review History    Comments

Our Contacts

Guest House Road, Street no - 1/6,
Hooghly, West Bengal,

+91 8617752708


Third Floor, 207 Regent Street
London, W1B 3HH,

+44 20-3031-1429